Rituxim

Rituxim is a CD20-directed cytolytic antibody indicated for the treatment of patients with: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies. Initial dose for NHL and CLL is 375 mg/m2 in first cycle. Rituxim vials 100 mg and 500 mg are stable at 2°C−8°C & solutions for infusion may be stored at 2°C−8°C (36°F−46°F) for 24 hours. 

Features